Alzheimer's Therapy Drug: Should We Pay $56,000 to Slow the Loss of Mom's Mind?
3 years ago
1.04K
Aduhelm sparks controversy as a therapy drug for Alzheimer's patients that attacks amyloid plaques in the brain, and slows the decline of memory and problem-solving by about 25% over time. It's not a cure, and it can't even restore lost mental capabilities. Now that the FDA has fast-tracked approval, should American taxpayers cover the $56,000/year per patient cost for relative minor results?
Scott Ott, Stephen Green and Bill Whittle create 240 new episodes of Right Angle annually, thanks to our Members. Join us now at https://BillWhittle.com
Loading 19 comments...
-
15:04
Bill Whittle: Conservative Opinion | Humor
14 days ago $3.52 earnedSONIC (boom)
2.62K10 -
1:21:51
TheDAMpodcast
3 years ago $0.06 earnedWhen and why should anyone take therapy?
931 -
3:56
NEWSMAX
3 years agoFDA APPROVES NEW ALZHEIMER'S DRUG
1.9K23 -
1:11
IOL-IndependentOnline
3 years ago $0.01 earnedFirst patient receives controversial Biogen Alzheimer's drug
32 -
1:56
KGUN
3 years agoHikers should keep heat safety in mind
2 -
5:10:45
Drew Hernandez
16 hours agoTRUMP RALLY UNIONDALE NEW YORK
88.3K39 -
1:15:06
Michael Franzese
9 hours agoTrump assassination attempt & fact checking Harris | Michael Franzese LIVE! Ep. 18
90.1K42 -
1:55:58
Melonie Mac
9 hours agoGo Boom Live Ep 21!
71.3K18 -
1:40:08
Redacted News
10 hours agoSHOCK! Secret Service admits it CAN'T stop more Trump Assassination Attempts | Redacted Live
192K306 -
50:56
Candace Show Podcast
10 hours agoExploding Pagers In Lebanon! Is This Terrorism? | Candace Ep 67
227K947